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Abstract
Objectives To assess the influence of region of interest (ROI)
size and positioning on tumour ADC measurements and
interobserver variability in patients with locally advanced rectal
cancer (LARC).
Methods Forty-six LARC patients were retrospectively in-
cluded. Patients underwent MRI including DWI (b0,500,1000)
before and 6–8 weeks after chemoradiation (CRT). Two readers
measured mean tumour ADCs (pre- and post-CRT) according
to three ROI protocols: whole-volume, single-slice or small
solid samples. The three protocols were compared for differ-
ences in ADC, SD and interobserver variability (measured as
the intraclass correlation coefficient; ICC).
Results ICC for the whole-volume ROIs was excellent (0.91)
pre-CRT versus good (0.66) post-CRT. ICCs were 0.53 and
0.42 for the single-slice ROIs versus 0.60 and 0.65 for the
sample ROIs. Pre-CRT ADCs for the sample ROIs were
significantly lower than for the whole-volume or single-slice
ROIs. Post-CRT there were no significant differences
between the whole-volume ROIs and the single-slice or
sample ROIs, respectively. The SDs for the whole-volume
and single-slice ROIs were significantly larger than for the
sample ROIs.
Conclusions ROI size and positioning have a considerable
influence on tumour ADC values and interobserver vari-
ability. Interobserver variability is worse after CRT. ADCs
obtained from the whole tumour volume provide the most
reproducible results.
Key Points
￿ ROI size and positioning influence tumour ADC measure-
ments in rectal cancer
￿ ROI size and positioning influence interobserver variability
of tumour ADC measurements
￿ ADC measurements of the whole tumour volume provide
the most reproducible results
￿ Tumour ADC measurements are more reproducible before,
rather than after , chemoradiation treatment
￿ V ariations caused by ROI size and positioning should be
taken into account when using ADC as a biomarker for
tumour response
Keywords Diffusion magnetic resonance imaging.Rectal
neoplasms.Observer variation.Methodology.Apparent
diffusion coefficient
Introduction
At present, the standard treatment for patients with locally
advanced rectal cancer consists of a long course of
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surgical resection. As surgery is routinely performed in each
patient—regardless of the response to treatment—response
evaluation after CRT has so far not been a major issue.
Nowadays there is, however, a trend towards minimally
invasive treatments instead of standard surgery for well-
responding patients [1–3]. Accurate response assessment then
becomes relevant, as it may directly influence treatment
planning.
18F-Fluorodeoxyglucose-Positron Emission Tomog-
raphy (FDG-PET) and MRI have been most extensively
studied for response evaluation, but these techniques suffer
from limitations in the interpretation of fibrotic scar tissue and
inflammation [4, 5]. Diffusion-weighted MR Imaging (DWI)
is a functional imaging technique that analyses differences in
the extracellular movement of water protons to discriminate
between tissues of varying cellularity [6]. Different publica-
tions on DWI have shown its potentially beneficial role for the
detection and characterisation of malignant tumours [7–9]. In
addition, changes in tumour diffusion during and after
treatment are indicative of tissue changes on a cellular level
and may be used to evaluate treatment response [10, 11].
Previous studies in a variety of tumour types have suggested
that quantitative interpretation of the apparent diffusion
coefficient (ADC) can be used as a biomarker for response
to treatment [12–15]. For rectal cancer patients specifically, a
benefit for treatment response evaluation by measuring
tumour ADC values before [16–19], during [16–18, 20, 21],
and after chemoradiation treatment has been suggested [22,
23]. Nevertheless—as also previously pointed out in a review
by Patterson et al. [10]—there is no consensus yet on the true
clinical value of ADC measurements for response assessment
in rectal cancer. This is because the available literature consists
of mainly small-scale studies with conflicting results. More-
over, in most studies, DWI evaluation was only performed by
a single reader and ADC measurements by a variety of
methods for region of interest (ROI) placement. Whereas
some authors included the whole tumour volume [17–19, 22,
24], others included only a single tumour slice [16, 21]o r
small tumour samples [23], which may contribute to the large
variety in reported ADC results. It remains unclear whether
ROIs for ADC measurements should ideally incorporate the
entire tumour volume or only a representative tumour section.
Furthermore, none of the studies focusing on rectal tumour
ADC have addressed the issue of interobserver variability,
which is a non-negligible factor when considering the use of
ADC as a potential marker for response in clinical practice.
The purpose of the current study is to assess the
influence of ROI size and positioning on interobserver
variability and ADC values when measuring tumour ADC
before and after chemoradiation treatment in patients with
locally advanced rectal cancer. We aim to determine which
method offers the most reproducible results in order to
provide a reference for further studies.
Materials and methods
Patients
This study retrospectively evaluated 46 patients who were
treated for locally advanced rectal cancer between 2006 and
2010. Clinical patient data were retrieved from a patient
database originating from a previous imaging study
approved by the local institutional review board, for which
the patients provided written informed consent. Thirty-four
patients were male and 12 were female. Median age was
70 years (range 49–88). Inclusion criteria consisted of [a]
histologically (biopsy) proven rectal adenocarcinoma, [b]
locally advanced disease, defined on primary staging T2-
weighted MRI by an experienced gastrointestinal radiolo-
gist as tumour in the distal rectum (≤5 mm from the
anorectal junction), threatened or involved circumferential
resection margins (≤2 mm margin between the tumour and
mesorectal fascia) and/or positive nodal stage (≥1 suspi-
cious nodes, i.e. >5 mm in size and/or heterogeneous signal
intensity and/or irregular border), [c] treatment consisting
of a long course of preoperative CRT (50.4 Gy radiation+
2×825 mg/m
2/day capecitabine) followed by surgical
resection and [d] availability of pre- and post-CRT MR
imaging including DWI. Patients with non-resectable and/
or metastatic disease were excluded. Mucinous tumours are
known to have a very low cellular density and will
therefore exhibit high ADC values [25]. As this may bias
the study results, patients with predominantly mucinous
appearing tumours (identified as predominantly high signal
lesions on T2-weighted MRI) were also excluded.
MR imaging
Patients did not receive bowel preparation or spasmolytics.
Imaging was performed at 1.5 T (Intera; Philips Medical
Systems, Best, The Netherlands) using a phased array body
coil. All patients underwent a pre-treatment MRI for
primary tumour staging and a second, restaging MRI for
response evaluation 6–8 weeks after completion of CRT.
The imaging protocol consisted of standard 2D T2-
weighted (T2W) fast spin-echo sequences (FSE) in three
orthogonal directions and an axial DWI single-shot echo
planar imaging sequence, according to the method of
diffusion-weighted imaging with background body signal
suppression (DWIBS), acquired with b-values of 0,500 and
1000 s/mm
2 [26]. The sequence parameters are displayed in
Table 1. The axial T2Wand DWI sequences were angled in
identical planes and were planned perpendicular to the
tumour axis as defined on sagittal MRI. ADC maps in
greyscale were automatically generated at the operating
system, using a monoexponential decay model including all
three b-values.
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The MR images were independently analysed by two
radiological researchers (DMJL and TT), who performed
tumour ADC measurements on the pre- and post-
chemoradiation images. The readers were blinded to each
other’s results, the clinical patient data and pathology reports.
Mean tumour ADC was evaluated by manually drawing
regionsofinterest(ROI)onthehighb-value(b1000)diffusion
images and copying them to the corresponding ADC map
(Fig. 1). The mean ADC+ standard deviation (SD) and the
number of pixels per ROI was recorded for each individual
measurement. On the pre-treatment b1000 diffusion images,
tumour was defined as a focal mass showing high signal
intensity compared with the signal of the normal adjacent
rectal wall and corresponding with the tumour (mass
showing intermediate signal intensity) on the anatomical
T2-weighted MRI. On the post-chemoradiation DWI, tumour
was defined as focal areas of residual high signal on the
b1000 images within the location of the primary tumour bed
and/or corresponding with residual tumour on T2-weighted
MRI (Fig. 2). The pre-treatment images were at the readers’
disposal when analysing the post-treatment images, in order
to compare and identify the location of the tumour. When no
remaining high signal could be visualised on DWI, three
sample measurements were obtained of the rectal wall at the
former location of the primary tumour, of which an example
is illustrated in Fig. 3.
ROI protocols
Mean tumour ADCs were measured according to three
distinct ROI protocols: [a] ‘Whole-volume’, [b] ‘Single-
slice’ and [c] ‘Solid tumour samples’. For the whole -
volume method, freehand ROIs were drawn along the
border of the high signal of the tumour on the b1000
images to cover the entire tumour area of each consecutive
tumour-containing slice. Mean ADC (+SD) was obtained
for each slice and ADC values were averaged to calculate
the mean ADC of the whole tumour volume. For the single-
Table 1 Sequence parameters
*D W Iw a sa c q u i r e dw i t hb -
values of 0, 500 and 1000 s/mm
2
T2W FSE DWI*
Repetition time (ms) 3427–8456 4829
Echo time (ms) 130–150 70
Echotrain length 25 1
In plane resolution (mm × mm) 0.78×1.14 2.50×3.11
Section thickness (mm) 3–55
Section gap (mm) 2 −1
No. of sections 22–30 50
No. of signals acquired 6 4
Sensitivity encoding (SENSE) factor - 2
Echo planar imaging (EPI) factor - 53
Acquisition time (min) 5.08–6.03 10.37
Fig. 1 Axial T2-weighted image (a), b1000 diffusion image (b) and
ADC map (c) of a male patient with a tumour in the rectum. For the
whole-volume and single-slice methods, ADC was measured by
drawing freehand ROIs along the high signal intensity border of the
tumour on the b1000 images (b) to cover the entire tumour area. ROIs
were copied to the ADC map (c) to calculate ADC. For the solid
sample method, tumour ADC was measured by drawing three oval- or
round-shaped ROIs within the most solid tumour areas
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way (along the border of the tumour), but only on a single
slice containing the largest available tumour area. For the
third method, mean ADC was calculated from a sample of
three round/oval-shaped ROIs that were placed within the
most solid tumour part (as identified on T2W-MRI) of three
independent tumour-containing slices, which an example is
illustrated in Fig. 1.
Statistical analyses
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS, version 16.0, Inc.,
Chicago, IL, USA). Interobserver variability for the tumour
ADC measurements of the two readers for the pre- and
post-CRTADC measurements and for each individual ROI
method was analysed according to the method of Bland and
Altman and by calculating the intraclass correlation
coefficient (0.00–0.20 poor, 0.21–0.40 fair, 0.41–0.60
moderate, 0.61–0.80 good and 0.81–1.00 excellent correla-
tion). ADCs were averaged between the two observers for
further analyses. A paired samples t-test was used to
compare [a] the pre- and post-treatment ADCs and [b] the
tumour ADC values obtained by the three different ROI
methods. For each patient, the average variance was
calculated over the different slice measurements, weighted
with the number of pixels. The mean SD for each patient
was calculated as the square root of the variance. The
variance (mean for the whole patient group) of the different
ROI measurement methods and for the pre- and post-CRT
measurements was compared using the F-statistics with
the total number of slices as the degree of freedom. P
values <0.05 were considered statistically significant.
Results
Patient and treatment characteristics
Twenty-seven patients underwent a low anterior resection,
15 an abdominoperineal resection and 4 more extended
surgery. At histology 6 patients had a ypT0, 5 ypT1, 14
Fig. 2 Axial pre- (a) and post-treatment (b) T2-weighted images of a
male patient with a rectal tumour. After treatment, the tumour has
undergone mainly fibrotic changes (arrowheads). On the corresponding
b1000 diffusion image, an ROI was drawn along a well-defined area of
high signal intensity within the fibrosis, suggestive of residual tumour.
At histology, a residual ypT2 tumour was found
Fig. 3 Axial T2-weighted images of a male patient with a rectal tumour
before (a)a n da f t e r( b) chemoradiation treatment. After CRT, the rectal
wall has normalised (arrowheads). On the corresponding b1000 diffusion
image (c), no high signal was observed and ROIs were placed within the
rectal wall at the location of the primary tumour to measure post-treatment
ADC. At histology, the patient had undergone a complete response
Eur Radiol (2011) 21:2567–2574 2570ypT2, 20 ypT3 and 1 a ypT4 status. Thirty-three patients
had a ypN0, 9 ypN1 and 4 ypN2 status.
Effect of ROI methods
The mean tumour ADCs, SDs and total ROI sizes are
displayed in Table 2 for the pre- and post-treatment
measurements of each respective ROI protocol. Mean pre-
treatment tumour ADC was significantly lower when
measured by means of small sample ROIs, compared with
the whole-volume (p<0.001) or single-slice protocol (p<
0.001), respectively. For the post-CRT measurements there
were no significant differences in tumour ADC between the
whole-volume ROIs compared with the single-slice (p=
0.07) or small sample ROIs (p=0.08), respectively, but the
single-slice ROIs resulted in significantly higher ADCs
compared with the small sample ROIs (p=0.002). For the
pre-CRT measurements, the variance (SD) of the small
sample ROI measurements was significantly smaller than
for the whole-volume ROIs (p<0.001) and single-slice
ROIs (p=0.03), respectively. For the post-CRT measure-
ments, the variance of the small sample ROIs was also
smaller than that of the whole-volume ROIs (p=0.003) and
single-slice ROIs, although the latter difference was not
statistically significant (p=0.06). There were no significant
differences in tumour ADC or variance between the whole-
volume and single-slice approaches.
Interobserver variability
Intraclass correlation coefficients between the two readers
are provided in Table 3 for the three ROI protocols. The
interobserver reproducibility was excellent (ICC 0.91) for
the pre-CRT whole-volume ADC measurements, and good
(ICC 0.66) for the post-CRT measurements. For the single-
slice and solid sample ROIs, the ICCs ranged from 0.42 to
0.65. Figure 4 displays the Bland-Altman plots for the
whole-volume measurements performed pre- and post-CRT.
Discussion
The results of this study show that, when measuring ADC
in patients with locally advanced rectal cancer, tumour
ADC values and interobserver variability are highly
dependent on methods of ROI analysis. ADC measure-
ments obtained from the whole tumour volume are more
reproducible than those obtained from single-slice or small
sample measurements. In specific pre-treatment whole-
volume ADC measurements result in excellent interobserver
reproducibility.
The number and size of the ROIs affected the interob-
server agreement. When comparing the different ROI
protocols, the single-slice and sample ROIs resulted in
considerably poorer interobserver agreement (ICC 0.42–
0.65) than the whole-volume ROIs (ICC 0.66–0.91),
indicating that analysing a larger number of pixels results
in more reproducible ADC values. Interobserver agreement
for the whole-volume ADC measurements before treatment
was excellent (ICC 0.91), but results after treatment were
poorer (ICC 0.66). After chemoradiation, rectal tumours
Table 2 Influence of choice of
regions of interest (ROIs)
Note.-ADCs and ROI sizes were
compared by means of a
paired t-test. SDs were com-
pared as variances by means
of F-statistics
* indicates a significant
difference compared with
whole-volume ROIs
** indicates a significant
difference compared with
single-slice ROIs
Pre-CRT Post-CRT P
Whole-volume ROIs
Mean ADC (*10
−3 mm
2/s) 1.10 1.44 <0.001
SD 0.26 0.25 0.41
Total ROI size (mm
2) 7275 767 <0.001
Single-slice ROIs
Mean ADC (*10
−3 mm
2/s) 1.10 1.48 <0.001
SD 0.24 0.23 0.35
Total ROI size (mm
2) 490* 157* <0.001
Solid sample ROIs
Mean ADC (*10
−3 mm
2/s) 1.02*
,** 1.41** <0.001
SD 0.19*
,** 0.20* 0.14
Total ROI size (mm
2) 696*
,** 220*
,** <0.001
Table 3 Interobserver variability (measured as the intraclass correla-
tion coefficient*) for the different ROI protocols
Pre-CRT Post-CRT
Whole-volume ROIs 0.91 0.66
Single-slice ROIs 0.53 0.42
Solid sample ROIs 0.60 0.65
* 0.00–0.20 poor; 0.21–0.40 fair; 0.41–0.60 moderate; 0.61–0.80
good; 0.81–1.00 excellent correlation
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a region of tumour residue within the fibrosis may be more
difficult (Fig. 5). In cases where the tumour has completely
regressed and the bowel wall has normalised or become
fibrotically thickened, it can be even more challenging to
correctly define an ROI (Fig. 3). After CRT, ADC measure-
ments thus seem to be more affected by the interpretation
skills of the reader than before CRT, when the tumour is
generally better defined.
The choice of ROIs also significantly influenced the
tumour ADC values. On pre-CRT MRI, the whole-volume
and single-slice ROIs resulted in significantly higher
tumour ADC values than the small sample ROIs. The
small sample ROIs only included the most viable solid
tumour parts, which may explain the lower ADC values. In
this setting, areas of necrosis are likely to be excluded from
the ADC measurements, while the presence of necrosis
before onset of treatment is in fact believed to be an
important indicator when aiming at evaluating response. A
previous study of Roth and co-authors showed that whole-
volume tumour ADC measurements were a better predictor
of response than ROIs chosen only from viable regions of
the tumour [18]. Although the focus in their study was on
perfusion CT in patients with colorectal cancer Goh et al.
also found that, when obtaining pharmacokinetic parame-
ters by applying different ROI sizes and positions, whole
tumour volume measurements were the most reliable [27].
The above-described phenomenon may also explain why
the whole-volume ADC measurements resulted in a larger
variance and higher standard deviations, which is likely to
Fig. 4 Interobserver reproducibility for the whole-volume tumour ADC
measurementsperformedpre-andpost-chemoradiationtreatment.Bland-
Altman plots of the mean ADC of the two observers (x-axis) against the
difference in ADC between the two observers (y-axis). The continuous
lines represent the mean absolute difference (bias) in ADC between the
two observers; the dashed lines represent the 95% confidence intervals of
the mean differences (limits of agreement)
Fig. 5 Axial T2-weighted images of a male patient with a rectal tumour
before(a) and after (b) chemoradiation treatment. An ill-defined residual
area of hypointense signal intensity, indicative of fibrosis, is visible after
CRT (arrowheads). On the corresponding diffusion image (c)t h e r ei s
still an area of high signal intensity, suggestive of residual tumour
(arrows). Because of its irregular aspect and ill-defined borders,
however, it is difficult to delineate an ROI, explaining the relatively
poor interobserver agreement for the post-CRTADC measurements. At
histology, a ypT1 residual tumour was found
Eur Radiol (2011) 21:2567–2574 2572reflect the heterogeneous nature of the tumour, including
solid foci, as well as areas of necrosis and fibrosis.
Altogether these findings suggest that whole-volume
measurements might be a better indicator of tumour
viability and may therefore be more suitable for assessment
of response. Furthermore, as was also stressed by Goh et al.
[27], if variations in ROI substantially influence the
measurements, efforts should be made to standardize their
application for clinical use. Interestingly, we observed no
significant differences in tumour ADC or SD between the
whole-volume measurements and the single-slice approach,
suggesting that the latter may also be used as a less time-
consuming alternative. However, one should keep in mind
that the single-slice method was subject to a much larger
interobserver variability and whole-volume measurements
thus remain the single most reliable method.
Our study is limited because of its retrospective nature
and the relatively small patient numbers. Furthermore, it
was sometimes difficult to position regions of interests due
to susceptibility artefacts occurring around air-tissue inter-
faces. This was especially challenging after chemoradiation,
in cases where only a limited or no residual tumour could
be identified on DWI. Susceptibility artefacts might be
minimised by applying rectal wall distension with intra-
luminal filling, which we have not done in the current
study. The specific focus of this study was to determine the
effect of ROI size and positioning on tumor ADC
evaluation and not to assess the relation between ADC
and response, as various previous authors have done [16–
24]. As such, we chose not to include a correlation between
ADC and histopathological parameters of response.
In conclusion, variations in ROI size and positioning
have a significant effect on tumour ADC values and
interobserver variability. The most reproducible results are
obtained when measuring ADC of the whole tumour
volume. Interobserver variability is larger after chemo-
radiation treatment than before. These issues should be
taken into account when considering the use of ADC as a
potential biomarker for response in clinical practice.
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